shroom family member 4Genealiases: MRXSSDS · SHAP · shrm4
Q-omics provides the consensus-scored SHROOM4 profile across patient tissues and cancer cell-line models. SHROOM4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SHROOM4 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SHROOM4 RNA expression shows 22,277 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where SHROOM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHROOM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHROOM4 survival associations across molecular data types. SHROOM4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHROOM4 RNA expression–survival associations across cancer types. High SHROOM4 expression shows unfavorable associations in UVM, LUSC, MESO and ACC, but favorable associations in KIRC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SHROOM4 RNA expression.
This table summarizes SHROOM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SHROOM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHROOM4 shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in COAD, THCA and LIHC. The COAD box plot shows higher SHROOM4 RNA expression in tumor versus normal tissue (log2 FC = +1.558, t-test p < 0.001).
This table shows molecular features associated with SHROOM4 in patient tissues and cancer cell lines. In patient samples, SHROOM4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SHROOM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
